More articles from From the editor
- Clinical trials: More to learn than the results
The details of the GIACTA trial challenge and reaffirm some of our clinical impressions about giant cell arteritis.
- The return of measles—an unnecessary sequel
Why are we having such a tough time convincing people to get routine vaccines for themselves and for their kids?
- Infection or not infection, that is the question—Is procalcitonin the answer?
What is different about procalcitonin that allows it to succeed as a biomarker where CRP and the ESR have failed?
- Can a humanities background prevent physician burnout?
Osler urged physicians to study the humanities. Can it prevent professional dissatisfaction and burnout?
- The tests that we order define us
In practice we balance the inputs from Watson, “Dr. Google,” our experience, and the specific data from the patient.
- There is more to the TSH than a number
Management of subclinical hypothyroidism should be nuanced and based on clinical and laboratory parameters.
- MGUS: It’s about the protein, not just the marrow
What is a cause of a high erythrocyte sedimentation rate with a normal C-reactive protein and a low anion gap?
- A new reason to reconsider that antibiotic prescription: The microbiome
Prescribing an antibiotic is a far more complicated and long-lasting affair than most of us thought.
- A physician’s response to observational studies of opioid prescribing
Not long ago, we were told we needed to do better at relieving pain.
- Small fibers, large impact
The wide interest in small fi ber neuropathy may reflect our current apparent epidemic of chronic pain.